ArticleEuropean journal of ophthalmology2026
Evaluating surgical experience in trabeculectomy: Insights from a single-surgeon learning curve.
Article in European journal of ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PurposeThe aim of our study was to evaluate the outcome of trabeculectomy with respect to surgeon's experience and to explore additional contributing factors.MethodsThis retrospective study was conducted analyzing consecutive single-surgeon cases from October 2019 to June 2022 receiving TE with mitomycin C. Eyes were categorized into five groups based on surgeon experience: E1 for the first 50 TEs, E2 for 51-100, E3 for 101-150, E4 for 151-200, E5 for 201-300. Complete success at one year was defined as an IOP <18 mmHg and 20%-IOP reduction without glaucoma eye drops and revision surgeries.Results300 eyes were included (mean age 68.8 ± 13.0 years, 58.3% female). 55.7% had primary open-angle glaucoma. The baseline IOP was 23.4 ± 8.7 mmHg with 3.0 ± 0.9 different antiglaucomatous medication. After 12 months, the complete success for E1 to E5, it was 83.0%, 86.7%, 87.4%, 75.3% and 79.1% (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.